MEDICAL DISTRIBUTION

Sep 28, 2026

Cencora (NYSE: COR) has outperformed the market over the past five years, generating an average annual return of 20.45%. An initial investment of $100 in Cencora five years ago would now be worth $254.34. The article highlights the significant impact of compounded returns on wealth growth over time.

Sep 28, 2026

DataMeds AI, in partnership with Tollo Health, has launched the "Health Lives Here" mobile application. This platform integrates GLP-1 telehealth services, pharmacy fulfillment, nutritional products, and health tracking, initially targeting patients using GLP-1 receptor agonist medications. The company plans to expand its services to include Long COVID and cancer patients, and intends to build a network with Corexa Health's independent pharmacies, beginning with a location in Concord, North Carolina.

Sep 26, 2026

Cencora (COR) has appointed Robert Sanchez, from Ryder Systems, as a new independent director to its board, effective October 1. This strategic election aims to bring Sanchez's expertise to Cencora's leadership.

Sep 25, 2026

This article analyzes the Q2 performance of several dental equipment and technology stocks, highlighting Dentsply Sirona (XRAY), Envista (NVST), Align Technology (ALGN), and Henry Schein (HSIC). It details their revenue growth, performance against analyst estimates, and stock price reactions, noting that the sector experienced strong Q2 revenues but subsequent stock price declines. The piece also touches on broader market shifts, including concerns over AI and geopolitics impacting investor focus.

Sep 25, 2026

This article compares AbbVie and Pfizer, two pharmaceutical giants, for investors looking at 2026. AbbVie is transitioning its focus to newer immunology drugs, while Pfizer is pursuing aggressive acquisitions in oncology and metabolic assets to counter post-pandemic revenue declines and upcoming patent expirations. While both offer significant dividends, Pfizer appears to be the more undervalued stock based on current valuation metrics, despite AbbVie's promising pipeline.

Sep 25, 2026

This article compares AbbVie and Pfizer, two pharmaceutical giants, for investors in 2026, analyzing their financial performance, product pipelines, and risk profiles. While AbbVie is transitioning from its Humira era with new immunology leaders, Pfizer is focusing on oncology and metabolic assets through acquisitions, navigating post-pandemic changes and patent expirations. The author ultimately suggests Pfizer is currently undervalued despite AbbVie's promising pipeline, due to Pfizer's lower valuation metrics and recent growth in its oncology business.

Sep 25, 2026

McKesson (MCK) recently raised its full-year adjusted EPS guidance, leading to investor reassessment despite a recent share price dip. While the stock has seen strong long-term gains, short-term momentum has cooled, prompting questions about its current valuation. Analysts, based on a "most followed view," suggest McKesson is still 11% undervalued, with a fair value of $980.73, driven by its focus on oncology and access platforms.

Sep 25, 2026

Cardinal Health Inc. (CAH) stock declined by 1.08% on Friday, closing at $220.22, despite an overall positive trading session for the broader market. The S&P 500 Index and Dow Jones Industrial Average both saw gains. The company's stock is currently trading 14.74% below its 52-week high achieved on August 11th.

Sep 25, 2026

Henry Schein, Inc. (HSIC) is outperforming the Dow Jones Industrials Average ($DOWI) year-to-date and over the past 52 weeks, driven by strong internal sales, dental merchandise gains, and strategic acquisitions. The company's Q2 results exceeded Wall Street expectations for both EPS and revenue, contributing to a "Moderate Buy" rating from analysts. HSIC continues to focus on digital transformation and long-term growth through its BOLD+1 plan and investments in technology.

Sep 25, 2026

Henry Schein Inc. reported strong Q2 2026 financial results with significant sales and non-GAAP EPS growth, leading to an increased full-year guidance. The company highlighted strategic initiatives including AI-enabled technology platforms, accelerated sales of own-brand products, and medical business expansion. Value creation efforts are on track to achieve $200 million in operating income improvements, with a focus on enhancing customer experience and driving sustainable shareholder value.

Sep 24, 2026

This article compares Cardinal Health (CAH) and McKesson (MCK), two major players in U.S. pharmaceutical distribution. While both are positioned for growth and leverage specialty pharmaceuticals and technology, Cardinal Health shows stronger earnings momentum, better valuation, and a more favorable estimate revision trend. McKesson, despite its scale and specialty services, exhibits less valuation differentiation and a weaker momentum score.

Sep 24, 2026

The article compares Cardinal Health (CAH) and McKesson (MCK), two direct competitors in U.S. pharmaceutical distribution, evaluating their recent performance, growth strategies, and valuation. It concludes that while both are strong companies, CAH currently presents a more compelling investment due to its stronger projected EPS growth, favorable valuation, and estimate momentum, despite both holding a Zacks Rank #3 (Hold).